Venrock Healthcare Capital Par Purchases 8,971 Shares of Oruka Therapeutics, Inc. (NASDAQ:ORKA) Stock

Oruka Therapeutics, Inc. (NASDAQ:ORKA) major shareholder Venrock Healthcare Capital Par bought 8,971 shares of Oruka Therapeutics stock in a transaction dated Wednesday, February 12th. The stock was purchased at an average cost of $11.86 per share, for a total transaction of $106,396.06. Following the completion of the acquisition, the insider now directly owns 4,044,684 shares of the company’s stock, valued at approximately $47,969,952.24. The trade was a 0.22 % increase in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink. Major shareholders that own at least 10% of a company’s stock are required to disclose their sales and purchases with the SEC.

Venrock Healthcare Capital Par also recently made the following trade(s):

• On Friday, February 14th, Venrock Healthcare Capital Par acquired 88,794 shares of Oruka Therapeutics stock. The shares were acquired at an average price of $11.44 per share, with a total value of $1,015,803.36.
• On Monday, February 10th, Venrock Healthcare Capital Par purchased 574 shares of Oruka Therapeutics stock. The stock was acquired at an average cost of $10.90 per share, with a total value of $6,256.60.

Oruka Therapeutics Stock Down 9.2 %

Shares of NASDAQ ORKA opened at $9.56 on Friday. The company has a 50 day moving average price of $14.49. The stock has a market capitalization of $334.59 million, a price-to-earnings ratio of -1.53 and a beta of 0.77. Oruka Therapeutics, Inc. has a 52-week low of $9.53 and a 52-week high of $53.88.

Analyst Ratings Changes

Several equities research analysts have recently issued reports on ORKA shares. Wolfe Research initiated coverage on shares of Oruka Therapeutics in a report on Tuesday, February 4th. They issued an “outperform” rating and a $20.00 target price for the company. HC Wainwright reissued a “buy” rating and issued a $45.00 price objective on shares of Oruka Therapeutics in a research note on Friday, February 7th. Finally, Wedbush reaffirmed an “outperform” rating and set a $40.00 target price on shares of Oruka Therapeutics in a research note on Tuesday, November 19th. Seven investment analysts have rated the stock with a buy rating and two have issued a strong buy rating to the company’s stock. Based on data from MarketBeat.com, Oruka Therapeutics presently has an average rating of “Buy” and an average target price of $39.86.

Institutional Investors Weigh In On Oruka Therapeutics

Several hedge funds have recently made changes to their positions in ORKA. JPMorgan Chase & Co. bought a new position in shares of Oruka Therapeutics during the fourth quarter valued at approximately $54,000. AlphaCentric Advisors LLC purchased a new position in Oruka Therapeutics in the fourth quarter valued at about $119,000. China Universal Asset Management Co. Ltd. bought a new position in shares of Oruka Therapeutics during the 4th quarter worth approximately $144,000. Squarepoint Ops LLC purchased a new stake in shares of Oruka Therapeutics during the 4th quarter valued at $236,000. Finally, Charles Schwab Investment Management Inc. acquired a new position in Oruka Therapeutics during the 4th quarter valued at about $303,000. 56.44% of the stock is currently owned by hedge funds and other institutional investors.

Oruka Therapeutics Company Profile

Oruka Therapeutics, Inc is a biotechnology company, which focuses on developing novel monoclonal antibody therapeutics for PsO and other I&I indications. Its pipeline includes ORKA-001 and ORKA-002. The company is headquartered in Menlo Park, CA.